Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Cabometyx tablets

Release date: 2024-07-09 16:45:22     Recommended: 96

04L0958_23卡博替尼 批文_00.jpg

Cabometyx tablets are suitable for the treatment of advanced renal cell carcinoma (RCC) patients, and in combination with nivolumab, they are suitable for first-line treatment of advanced RCC patients; Suitable for treating hepatocellular carcinoma (HCC) patients who have previously received sorafenib treatment; Suitable for treating adult and pediatric patients aged 12 and above with locally advanced or metastatic differentiated thyroid cancer (DTC), who have progressed after previous VEGFR targeted therapy and are refractory or unqualified to radioactive iodine.

Company News

Research News

Drug news